The present consensus panel recommendations of the 36th Bethesda Conference for eligibility and disqualification of competitive athletes are predicated on the prior diagnosis of cardiovascular abnormalities. However, the methodology by which these diseases are identified (including preparticipation screening) and how athletes come to evaluation for competitive eligibility, may involve several scenarios. First, athletes may be referred for assessment of clinical symptoms or signs. Second, fortuitous recognition may occur in routine clinical practice, triggered by findings on history and physical examination, such as a heart murmur. Third, young athletes may be suspected of having cardiovascular disease by virtue of formalized large population screening examinations that are customary before participation in competitive athletics (1).

PREPARTICIPATION SCREENING

Indeed, the ultimate objective of preparticipation screening carried out in general populations of trained athletes is the recognition of "silent" cardiovascular abnormalities that can progress or cause sudden cardiac death. Such screening efforts have the capability of raising the clinical suspicion of several cardiovascular diseases—usually by virtue of a heart murmur, regarded to be of potential clinical significance, cardiac symptoms (e.g., exertional chest pain, disproportionate dyspnea, or impairment in consciousness), or a family history of heart disease or sudden unexpected death. However, a major obstacle to implementation of large-scale screening in the U.S. is the substantial number of young athletes eligible for evaluation (about 10 to 12 million) and the rarity of the cardiac diseases capable of causing sudden death in this population (estimated prevalence, less than or equal to 0.3%) (2).

Customary screening strategies for U.S. high school and college athletes, particularly the design of approved questionnaires, has come under scrutiny regarding inadequacies (5,6) when measured against American Heart Association (AHA) recommendations (1) (Table 1). Legislation in several states allows health care workers with vastly different levels of training and expertise (including chiropractors and naturopathic clinicians) to conduct preparticipation sports examinations, often under suboptimal conditions. Improvement in this screening process, including the training level of examiners, would undoubtedly result in a greater number of athletes identified with previously unsuspected but clinically relevant cardiovascular abnormalities. Indeed, development and dissemination of a standardized and uniform national preparticipation history and physical examination form for medical screening in all high schools and colleges (which incorporates the AHA recommendations) would be the most practical approach for achieving this goal.

Certainly, the diagnosis of genetic diseases, such as HCM, arrhythmogenic right ventricular cardiomyopathy (ARVC), long QT and Brugada syndromes, and other inherited arrhythmia syndromes in asymptomatic patients has now taken on even greater relevance. This is because individuals judged to be at sufficiently high-risk may be eligible for primary prevention of sudden cardiac death with an implantable cardioverter-defibrillator (7,8).

Conversely, in Italy, for the past 25 years, a formal national preparticipation screening and medical clearance program has been mandated for young competitive athletes in organized sports programs (9,10). The Italian system is unique by virtue of requiring annual evaluations that routinely include a 12-lead electrocardiogram (ECG) as well as a history and physical examination; the ECG itself has proven most useful in the identification of many previously undiagnosed athletes with HCM (10). However, such screening efforts may be complicated by the substantial proportion of false-positive test results that potentially represent a major burden to athletes, their families, and the
testing in the vast majority of cases, and this will remain so.

Marfan syndrome continues to be made through clinical

diagnosis over the past decade, identification of

cases used only selectively in athletes suspected clini-

physiologic testing with programmed stimulation can be

approaches include echocardiography, ECG, history, and

known to cause sudden death in young athletes; these

should focus on the systematic exclusion of those conditions

formal screening or otherwise), the diagnostic strategy

When a cardiovascular abnormality is initially suspected (by

DIAGNOSTIC TESTING STRATEGIES

When a cardiovascular abnormality is initially suspected (by

formal screening or otherwise), the diagnostic strategy

should focus on the systematic exclusion of those conditions

known to cause sudden death in young athletes; these

approaches include echocardiography, ECG, history, and

physical examination. Additional noninvasive (and invasive)
testing with cardiac magnetic resonance imaging (CMR),

exercise testing, ambulatory Holter ECG recording, im-

planted loop recorder, tilt table examination, or electro-

physiologic testing with programmed stimulation can be

considered in selected patients. Diagnostic myocardial bi-

opsies are used only selectively in athletes suspected clini-

ically of myocarditis.

Despite considerable assembled data regarding DNA-

based diagnosis over the past decade, identification of

genetic cardiovascular diseases such as HCM, long QT

syndrome, and other ion-channel disorders, ARVC, and

Marfan syndrome continues to be made through clinical
testing in the vast majority of cases, and this will remain so

in the foreseeable future. At present, genetic testing is not
easily available on a routine clinical basis for most genetic

heart diseases, or for application to large athletic popula-
tions given the expensive and complex methodologies in-

volved and the genetic heterogeneity characteristic of these
diseases (12).

Echocardiography. Two-dimensional echocardiography is
the principal diagnostic imaging modality for clinical iden-
tification of HCM by demonstrating otherwise unexplained

and usually asymmetric left ventricular (LV) wall thickening

(12,13). In this regard, a maximal LV end-diastolic wall

thickness of 15 mm or more (or on occasion, 13 or 14 mm)
is the absolute dimension generally accepted for the clinical
diagnosis of HCM in an adult athlete (two or more standard
deviations from the mean relative to body surface area; Z-
score of two or more in children) (12,13); however, any

specific LV wall thickness (including normal) is theoretically

compatible with the presence of a mutant HCM gene

(12,14). Echocardiography would also be expected to detect

and define other specific and relevant congenital structural

abnormalities associated with sudden death or disease pro-

gression in young athletes such as valvular heart disease

e.g., mitral valve prolapse and aortic valve stenosis), aortic

root dilatation and mitral valve prolapse in Marfan or

related syndromes, and LV dysfunction and/or enlargement

evident in myocarditis and dilated cardiomyopathy). Such
diagnostic testing requires interpretation by physicians

trained in echocardiography, but cannot guarantee full

recognition of all relevant lesions, and some important
diseases may escape detection despite expert screening

methodology. For example, the HCM phenotype may not be

evident when echocardiography is performed in the

pre-hypertrophic phase (i.e., a patient less than 14 years

of age) (12). Annual serial echocardiography is recom-

mended in HCM family members throughout adoles-
icence (12,14).

Electrocardiography. The 12-lead ECG may be of use in

the diagnosis of cardiovascular disease in young athletes,

and has been promoted as a practical and cost-effective

strategic alternative to routine echocardiography for

population-based preparticipation screening. For example,

the ECG is abnormal in up to 75% to 95% of patients with

HCM, and often before the appearance of hypertrophy

(12). The ECG will also identify many individuals with the

long QT, Brugada, and other inherited syndromes associ-

ated with ventricular arrhythmias. It raises the suspicion of

myocarditis by premature ventricular complexes and ST-T

abnormalities, or ARVC by T-wave inversion in leads V1

through V3 and low amplitude potentials (epsilon waves)

(1,2). Of note, however, a not inconsequential proportion of

genetically affected family members with long QT syn-
drome may not express QT interval prolongation, and ECG

abnormalities are usually absent in random recordings from

patients with congenital coronary artery anomalies (4).

Other tests. In those cases in which the echocardiogram is

normal or borderline for LV hypertrophy, but a suspicion

<table>
<thead>
<tr>
<th>Table 1. AHA Consensus Panel Recommendations for Preparticipation Athletic Screening (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Family History</strong></td>
</tr>
<tr>
<td>1. Premature sudden cardiac death</td>
</tr>
<tr>
<td>2. Heart disease in surviving relatives less than 50 years old</td>
</tr>
<tr>
<td><strong>Personal History</strong></td>
</tr>
<tr>
<td>3. Heart murmur</td>
</tr>
<tr>
<td>4. Systemic hypertension</td>
</tr>
<tr>
<td>5. Fatigue</td>
</tr>
<tr>
<td>6. Syncope/near-syncope</td>
</tr>
<tr>
<td>7. Excessive/unexplained exertional dyspnea</td>
</tr>
<tr>
<td>8. Exertional chest pain</td>
</tr>
<tr>
<td><strong>Physical Examination</strong></td>
</tr>
<tr>
<td>9. Heart murmur (supine/standing*)</td>
</tr>
<tr>
<td>10. Femoral arterial pulses (to exclude coarctation of aorta)</td>
</tr>
<tr>
<td>11. Stigmata of Marfan syndrome</td>
</tr>
<tr>
<td>12. Brachial blood pressure measurement (sitting)</td>
</tr>
</tbody>
</table>

for HCM persists (often due to an abnormal 12-lead ECG), CMR may be useful in clarifying wall thickness or detecting segmental areas of hypertrophy in selected regions of the LV chamber which may be more difficult to image reliably with conventional echocardiography, such as anterolateral free wall or apex (15,16).

Definitive identification of congenital coronary artery anomalies of wrong sinus origin usually requires sophisticated laboratory imaging, including multi-slice computed tomography or coronary arteriography. However, in young athletes it is possible to raise the suspicion of these malformations with transthoracic or transesophageal echocardiography or CMR imaging. Often, ARVC cannot be diagnosed reliably with echocardiography, and CMR is probably the most useful noninvasive test for identifying the structural abnormalities in this condition (i.e., right ventricular enlargement, wall motion abnormalities, adipose tissue replacement within the wall, and aneurysm formation); however, CMR is not an entirely sensitive or specific diagnostic modality in ARVC (17).

Clinical distinctions between physiologic athlete’s heart and pathologic conditions (18–23) have critical implications for trained athletes, because cardiovascular abnormalities may trigger disqualification from competitive sports to reduce the risk of sudden death or disease progression. An over-diagnosis may lead to unnecessary restrictions, depriving athletes of the psychological, social, or possibly (in some elite athletes) economic benefits of sports (2).

Morphologic adaptations of athlete’s heart can closely resemble certain cardiovascular diseases and lead to a differential diagnosis with HCM, dilated cardiomyopathy, and ARVC (2) (Fig. 1). Such clinical dilemmas not infrequently arise when cardiac dimensions fall outside clinically accepted partition values. For example, 2% of highly trained adult male athletes show relatively mild increases in LV wall thickness (13 to 15 mm) and 15% have LV cavity enlargement greater than or equal to 60 mm (2,21,22); both fall into a borderline and inconclusive “gray zone” for which extreme expressions of benign athlete’s heart and mild morphologic forms of cardiomyopathy overlap (2,22,23). Indeed, the two most common clinical scenarios encountered that unavoidably generate ambiguous diagnoses in trained athletes are: 1) differentiating HCM from athlete’s heart in athletes with an LV wall thickness of 13 to 15 mm, non-dilated and normally contractile LV, and absence of mitral valve systolic anterior motion; and 2) differentiating
early presentation of dilated cardiomyopathy from athlete’s heart with LV end-diastolic cavity dimension 60 mm or more with low-normal LV function (i.e., ejection fraction of 50% to 55%).

Such cases with diagnostic uncertainty are not uncommon and may be resolved in many athletes by a number of independent noninvasive clinical parameters, including the response of cardiac mass to short periods of deconditioning, or assessment of diastolic filling (22) (Fig. 2). Clarification of such diagnostic ambiguities may also be achieved with CMR imaging, genotyping, and serial acquisition of clinical and morphologic evidence over time.

doi:10.1016/j.jacc.2005.02.007

**TASK FORCE 1 REFERENCES**


Appendix 1. Author Relationships With Industry and Others

<table>
<thead>
<tr>
<th>Name</th>
<th>Consultant</th>
<th>Research Grant</th>
<th>Speaker’s Bureau</th>
<th>Stock Holder</th>
<th>Expert Witness</th>
<th>Testimony</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Barry J. Maron</td>
<td>None</td>
<td>Medtronic</td>
<td>None</td>
<td>None</td>
<td></td>
<td>1996, Defense, Northwestern vs. Knapp</td>
</tr>
<tr>
<td>Dr. Pamela S. Douglas</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Rick A. Nishimura</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Thomas P. Graham</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Paul D. Thompson</td>
<td>Astra Zeneca, Bristol Myers, Squibb</td>
<td>Astra Zeneca, Merck, Pfizer, Schering</td>
<td>Astra Zeneca, Merck, Pfizer, Schering</td>
<td>Pfizer, Schering</td>
<td>2005, Plaintiff, Sudden death in college athlete</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2004, Defense, Stress test/recreational sports</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2002, Sudden death, World Gym</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2002, Plaintiff, Sudden death, truck driver</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1998, Plaintiff, Sudden death, recreational sports</td>
<td></td>
</tr>
</tbody>
</table>

Task Force 2: Congenital Heart Disease

Thomas P. Graham, Jr, MD, FACC, Chair
David J. Driscoll, MD, FACC, Welton M. Gersony, MD, FACC,
Jane W. Newburger, MD, MPH, FACC, Albert Rocchini, MD, Jeffrey A. Towbin, MD, FACC

GENERAL CONSIDERATIONS

The most common congenital heart lesions that have been associated with sudden death during sports participation are hypertrophic cardiomyopathy, coronary artery anomalies, Marfan syndrome, and aortic valve disease (1–3). Less common lesions include complex defects, such as transposition and single ventricle, and those with associated pulmonary vascular disease.

The recommendations presented are intended to provide broad guidelines for patients with congenital heart defects (4). When questions about the safety of sports participation arise, there is no substitute for a comprehensive evaluation by a knowledgeable and experienced physician. Exercise testing can be useful, particularly if symptoms, the electrocardiogram (ECG), and blood pressure are monitored during conditions that simulate the sport in question. Arrhythmias discussed in this Task Force are usually identified by exercise testing or some form of long-term monitoring (including ambulatory Holter and event recording). Serial evaluations may be required because of changing hemodynamic status with time.

TYPES OF CONGENITAL DEFECTS

Atrial septal defect (ASD)—untreated. Most children with ASD are asymptomatic, and closure is usually carried out before they are active in competitive sports. An ECG and echocardiogram are required for evaluation. Small atrial defects are characterized by minimal or no right ventricular volume overload, moderate or large defects have significant volume overload but pulmonary hypertension is unusual.

Recommendations:
1. Athletes with small defects, normal right heart volume, and no pulmonary hypertension can participate in all sports.
2. Athletes with a large ASD and normal pulmonary artery pressure can participate in all competitive sports.
3. Athletes with an ASD and mild pulmonary hypertension can participate in low-intensity competitive sports (class IA). Patients with associated pulmonary vascular obstructive disease who have cyanosis and a large right-to-left shunt cannot participate in competitive sports.